Post Profile






EpiPen maker finalizes settlement for government overcharges

EpiPen maker Mylan has finalized a $465 million federal agreement settling allegations it overbilled Medicaid for its emergency allergy injectors for a decade — charges brought after rival Sanofi filed … Click to Continue »
read more

share

Related Posts


EpiPen Maker Mylan Will Pay $465 Million to Settle Medicaid Overcharging Case

Business & Finance : DealBook

Mylan said the settlement, after the government had said it improperly classified EpiPen as a generic drug, did not imply any admission of wrongdoing.

Mylan, U.S. finalize $465 million EpiPen settlement

Health : Reuters: Health

BOSTON (Reuters) - Mylan NV has finalized a $465 million settlement with the U.S. Justice Department resolving claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm o...

The maker of EpiPen has agreed to pay the government $465 million after allegedly overcharging for the medicine

Business & Finance : Business Insider: Money Game

Mylan, the marker of the EpiPen, has agreed to pay the federal government a $465 million settlement after it allegedly overcharged government healthcare agencies for the medicine, according to a release from the firm. Mylan had unde...

Mylan to pay $465-million settlement over Medicaid EpiPen rebates

Business & Finance : LA Times: Business

Mylan will pay $465 million to settle allegations that it overbilled Medicaid for its life-saving EpiPen allergy injection. The federal government says EpiPen is a branded drug, which means Mylan should have been paying a far higher...

EpiPen maker finalizes $465 million settlement with New York-led state-federal coalition

United States / New York : Crain's New York Business

EpiPen maker Mylan has finalized a $465 million government agreement settling allegations it overbilled Medicaid for its emergency allergy injectors for a decade—charges brought after rival... To view the full story, click the title...

Comments


Copyright © 2016 Regator, LLC